Chemotherapy toxicity assessment using a self-report tool.

P Brinkman; D Hay; P Laubinger

PubMed · 7854935

Chemotherapy toxicity assessment using a self-report tool.

Abstract

PURPOSE/OBJECTIVES: To improve the data collection process for patients participating in clinical trials and to ensure patient safety. DATA SOURCES: Clinical trial toxicity assessment forms and clinical experience. DATA SYNTHESIS: A comprehensive self-report form was developed to collect information regarding the toxicity experienced. The form was designed to be easy for patients to complete and nurses/physicians to interpret. CONCLUSIONS: Preliminary evaluation indicates that a self-administered form provides accurate and more complete information regarding chemotherapy toxicity than a simple patient interview. It is not limited by the setting. IMPLICATIONS FOR NURSING PRACTICE: The self-report form allows the nurse to assess chemotherapy toxicity and to make dose modifications as necessary, regardless of the patient's clinical trial status.

Explore related subjects

Antineoplastic Combined Chemotherapy Protocols Forms and Records Control Humans Medical Records Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P Brinkman, D Hay, P Laubinger. Chemotherapy toxicity assessment using a self-report tool.. https://pubmed.ncbi.nlm.nih.gov/7854935/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Treatment of metastatic sialoblastoma with chemotherapy and surgery.

Tumors of the salivary gland are very uncommon in children. Sialoblastoma is a rare, aggressive, blastomatous, and potentially malignant congenital tumor. Distant metastases are rare. We present a case of sialoblastoma with lung metastases that developed in a 4-year-old girl adjacent to a congenital nevus in the left cheek. The tumor was inoperable at diagnosis but the largest of the pulmonary metastases was removed surgically. The patient responded well to chemotherapy and underwent surgical excision of the primary tumor, followed by three more courses of chemotherapy.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed2008

Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide.

Anaplastic large cell lymphoma (ALCL) accounts for approximately 15% of childhood NHL. Relapsed ALCL represents a formidable challenge because outcome is poor despite the use of high-dose chemotherapy regimens. We report two patients with relapsed T-type and 0-type ALCL who achieved long-term 3rd and 4th remissions with 4-weekly oral dexamethasone (DEX) and etoposide pulses for 2 years. This regimen also induced and maintained remission in a third patient with Nijmegen breakage syndrome (NBS) with secondary T-type ALCL. These patients demonstrate that low-intensity oral chemotherapy can induce long-term remissions and offer a curative perspective in refractory, relapsed and secondary ALCL.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed2008

Stage III cystic partially differentiated nephroblastoma recurring after nephrectomy and chemotherapy.

Cystic partially differentiated nephroblastoma (CPDN) has low malignant potential. We report a 1-year-old with stage III CPDN of the right kidney that recurred following radical nephrectomy and chemotherapy. There was evidence of tumor spillage pre-operatively and intra-operatively. During chemotherapy the disease recurred in the omentum and the peritoneum. Pathology of the recurrent resected cysts revealed a more differentiated biphasic tumor without blastemal elements. It appears that spillage of CPDN in our patient led to dissemination of disease. Chemotherapy failed to prevent recurrence but only mature elements were present following this treatment. The intensity of therapy required to treat CPDN remains undefined.

Antineoplastic Combined Chemotherapy Protocols↗